Lecanemab-Irmb: uses, dosing, side effects & brands
Lecanemab-Irmb is a medicine sold in the U.S. under 2 brand and generic names, for alzheimer disease. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Alzheimer Disease
- Available as
- Injectable
- Sold as
- 2 products — Leqembi and Leqembi Iqlik
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
- Boxed warning
- Boxed warning
How lecanemab-irmb is dosed
From the FDA label for Leqembi (application BLA761269). Other lecanemab-irmb products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Confirm the presence of amyloid beta pathology prior to initiating treatment. ( 2.1 ) Obtain a recent baseline brain MRI prior to initiating treatment. ( 2.4 , 5.1 ) Obtain an MRI after 1, 2, 3, and 6 months of treatment. If radiographically observed ARIA occurs, treatment recommendations are based on type, severity, and presence of symptoms. ( 2.4 , 5.1 ) Recommended starting dosage: Intravenous infusion: 10 mg/kg once every 2 weeks administered after dilution as an intravenous infusion over approximately one hour. ( 2.2 , 2.5 ) Subcutaneous injection: 500 mg administered once a week using the LEQEMBI IQLIK autoinjector. ( 2.2 , 2.6 ). After 18 months, continue treatment with the starting dosage or transition to an intravenous or subcutaneous maintenance dosage. (2.2) Recommended maintenance dosage: Intravenous infusion: 10 mg/kg once every 4 weeks ( 2.2 , 2.5 ) Subcutaneous injection: 360 mg administered once a week using the LEQEMBI IQLIK autoinjector ( 2.2 , 2.6 ). See Full Prescribing Information for preparation and administration instructions. ( 2.5 , 2.6 ) 2.1 Patient Selection Confirm the presence of amyloid beta pathology prior to initiating treatment [see Clinical Pharmacology ( 12.1 )] . 2.2 Recommended Dosage Initiate LEQEMBI using a starting dosage regimen (see Table 1 ). After 18 months, the starting dosage regimen may be continued or a transition to a…
Lecanemab-Irmb side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: Amyloid Related Imaging Abnormalities [see Warnings and Precautions ( 5.1 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.2 )] Infusion-Related Reactions [see Warnings and Precautions ( 5.3 )] Most common adverse reactions (at approximately 10% and higher incidence compared to placebo): infusion-related reactions, amyloid related imaging abnormality-microhemorrhages, amyloid related imaging abnormality-edema/effusion, and headache. Additionally, injection-related reactions occurred in patients receiving subcutaneously administered LEQEMBI. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc. at 1-888-274-2378 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Clinical Trials with Intravenous Administration The safety of LEQEMBI has been evaluated in 2090 patients who received at least one dose of LEQEMBI by intravenous infusion. In Studies 1 and 2 in patients with Alzheimer’s disease, 1059 patients received LEQEMBI 10 mg/kg every two weeks by intravenous infusion…
Who shouldn’t take lecanemab-irmb
LEQEMBI is contraindicated in patients with serious hypersensitivity to lecanemab-irmb or to any of the excipients. Reactions have included angioedema and anaphylaxis [see Warnings and Precautions ( 5.2 )] . LEQEMBI is contraindicated in patients with serious hypersensitivity to lecanemab-irmb or to any of the excipients. ( 4 )
Every lecanemab-irmb product we track (2)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|
| 1 | Not yet rated | Prescription | Injectable | No data | — | View → | |
| 2 | Not yet rated | Prescription | Injectable | No data | — | View → |
What people report to the FDA about lecanemab-irmb
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 17 reports naming lecanemab-irmb, and the FDA flagged 41% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- infusion related reaction6 reports
- headache5 reports
- chills4 reports
- amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits3 reports
- dizziness3 reports
- hypoaesthesia3 reports
- muscular weakness3 reports
- arthralgia2 reports
Read these as a signal, not a rate. A report does not mean lecanemab-irmb caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is lecanemab-irmb?
Leqembi (Lecanemab-Irmb) is a medication used to treat Alzheimer Disease.
Can you take lecanemab-irmb with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run lecanemab-irmb against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is lecanemab-irmb sold under?
We track 2 lecanemab-irmb-containing products in the U.S.: Leqembi and Leqembi Iqlik. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does lecanemab-irmb come in?
Across the brands we track, lecanemab-irmb is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic lecanemab-irmb?
We do not currently list a generic-labelled lecanemab-irmb product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Lecanemab-Irmb: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/lecanemab-irmb
- MLA
- “Lecanemab-Irmb: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/lecanemab-irmb.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for lecanemab-irmb on DailyMed (NIH) ↗ — including its boxed warning in full.